Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

Minesh Mehta

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	38
State	Published - Oct 10 2020

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{21fa17803ce64744b0490519cf9324d9,

title = "Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma",

author = "Minesh Mehta",

note = "Journal of Clinical Oncology (2020) 38(29):3407-3417",

year = "2020",

month = oct,

day = "10",

language = "American English",

volume = "38",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

AU - Mehta, Minesh

N1 - Journal of Clinical Oncology (2020) 38(29):3407-3417

PY - 2020/10/10

Y1 - 2020/10/10

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3708

M3 - Article

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

Access to Document

Other files and links

Cite this